Literature DB >> 20959990

Long-term urinary adverse effects of pelvic radiotherapy.

Sean P Elliott1, Bahaa S Malaeb.   

Abstract

OBJECTIVE: Radiation for tumors arising in the pelvis has been utilized for over a 100 years. Adverse effects (AEs) of radiotherapy (RT) continue to accumulate with time and are reported to show decades after treatment. The benefit of RT for pelvic tumors is well described as is their acute AEs. Late AEs are less well described. The burden of treatment for the late AEs is large given the high utilization of RT. REVIEW: For prostate cancer, 37% of patients will receive radiation during the first 6 months after diagnosis. Low-and high-grade AEs are reported to occur in 20-43 and 5-13%, respectively, with a median follow-up of ~60 months. For bladder cancer, the grade 2 and grade 3 late AEs occur in 18-27 and 6-17% with a median follow-up of 29-76 months. For cervical cancer, the risk of low-grade AEs following radiation can be as high as 28%. High-grade AEs occur in about 8% at 3 years and 14.4% at 20 years or ~0.34% per year. Radiation AEs appear to be less common or at least less well studied after radiation for rectal and endometrial cancers.
CONCLUSION: Properly delineating the rate of long-term AEs after pelvic RT is instrumental to counseling patients about their options for cancer treatment. Further studies are needed that are powered to specifically evaluate long-term AEs.

Entities:  

Mesh:

Year:  2010        PMID: 20959990      PMCID: PMC3075494          DOI: 10.1007/s00345-010-0603-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  54 in total

1.  Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.

Authors:  Barby Pickett; John Kurhanewicz; Jean Pouliot; Vivian Weinberg; Katsuto Shinohara; Fergus Coakley; Mack Roach
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-06       Impact factor: 7.038

2.  Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

Authors:  Stephanie T H Peeters; Wilma D Heemsbergen; Peter C M Koper; Wim L J van Putten; Annerie Slot; Michel F H Dielwart; Johannes M G Bonfrer; Luca Incrocci; Joos V Lebesque
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

3.  Carcinoma of the cervix: analysis of complications after primary external beam radiation and Ir-192 HDR brachytherapy.

Authors:  K S Kapp; G F Stuecklschweiger; D S Kapp; J Poschauko; H Pickel; A Hackl
Journal:  Radiother Oncol       Date:  1997-02       Impact factor: 6.280

4.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Authors:  M J Zelefsky; D Cowen; Z Fuks; M Shike; C Burman; A Jackson; E S Venkatramen; S A Leibel
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

5.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.

Authors:  Louis Potters; Carol Morgenstern; Emil Calugaru; Paul Fearn; Anup Jassal; Joseph Presser; Edward Mullen
Journal:  J Urol       Date:  2005-05       Impact factor: 7.450

6.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Authors:  M J Zelefsky; T Hollister; A Raben; S Matthews; K E Wallner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-15       Impact factor: 7.038

7.  The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy.

Authors:  W Duncan; P M Quilty
Journal:  Radiother Oncol       Date:  1986-12       Impact factor: 6.280

8.  Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.

Authors:  Sean P Elliott; Maxwell V Meng; Eric P Elkin; Jack W McAninch; Janeen Duchane; Peter R Carroll
Journal:  J Urol       Date:  2007-06-13       Impact factor: 7.450

9.  Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Donald S Kaufman; Michael P Hagan; Niall M Heney; Howard M Sandler
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

10.  Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.

Authors:  Floris J Pos; Simon Horenblas; Joos Lebesque; Luc Moonen; Christoph Schneider; Peter Sminia; Harry Bartelink
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-01       Impact factor: 7.038

View more
  21 in total

Review 1.  [High urinary diversion after irradiation to the lesser pelvis].

Authors:  A Pycha; E Trenti
Journal:  Urologe A       Date:  2020-04       Impact factor: 0.639

2.  Nutritional supplementation with L-arginine prevents pelvic radiation-induced changes in morphology, density, and regulating factors of blood vessels in the wall of rat bladder.

Authors:  Waldemar S Costa; Monica N Ribeiro; Luiz E M Cardoso; Maria C Dornas; Cristiane F Ramos; Carla B M Gallo; Francisco J B Sampaio
Journal:  World J Urol       Date:  2012-08-30       Impact factor: 4.226

3.  Bladder and bowel symptoms in cervical and endometrial cancer survivors.

Authors:  Kristine A Donovan; Alice R Boyington; Patricia L Judson; Jean F Wyman
Journal:  Psychooncology       Date:  2014-01-30       Impact factor: 3.894

4.  MnTE-2-PyP Treatment, or NOX4 Inhibition, Protects against Radiation-Induced Damage in Mouse Primary Prostate Fibroblasts by Inhibiting the TGF-Beta 1 Signaling Pathway.

Authors:  Arpita Chatterjee; Elizabeth A Kosmacek; Rebecca E Oberley-Deegan
Journal:  Radiat Res       Date:  2017-02-22       Impact factor: 2.841

5.  Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.

Authors:  Kevin Shee; Claire M de la Calle; Albert J Chang; Anthony C Wong; Felix Y Feng; Alexander R Gottschalk; Peter R Carroll; Hao G Nguyen
Journal:  Adv Radiat Oncol       Date:  2022-03-12

6.  MnTE-2-PyP modulates thiol oxidation in a hydrogen peroxide-mediated manner in a human prostate cancer cell.

Authors:  Qiang Tong; Yuxiang Zhu; Joseph W Galaske; Elizabeth A Kosmacek; Arpita Chatterjee; Bryan C Dickinson; Rebecca E Oberley-Deegan
Journal:  Free Radic Biol Med       Date:  2016-09-24       Impact factor: 7.376

7.  Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study.

Authors:  H Lind; A-C Waldenström; G Dunberger; M al-Abany; E Alevronta; K-A Johansson; C Olsson; T Nyberg; U Wilderäng; G Steineck; E Åvall-Lundqvist
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

8.  Manganese porphyrin, MnTE-2-PyP, treatment protects the prostate from radiation-induced fibrosis (RIF) by activating the NRF2 signaling pathway and enhancing SOD2 and sirtuin activity.

Authors:  Shashank Shrishrimal; Arpita Chatterjee; Elizabeth A Kosmacek; Paul J Davis; J Tyson McDonald; Rebecca E Oberley-Deegan
Journal:  Free Radic Biol Med       Date:  2020-03-25       Impact factor: 7.376

9.  The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation.

Authors:  Rebecca E Oberley-Deegan; Joshua J Steffan; Kyle O Rove; Kathryn M Pate; Michael W Weaver; Ivan Spasojevic; Barbara Frederick; David Raben; Randall B Meacham; James D Crapo; Hari K Koul
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Body mass index can affect gastrointestinal and genitourinary toxicity in patients with prostate cancer treated with external beam radiation therapy.

Authors:  Hiroshi Doi; Fumiko Ishimaru; Masao Tanooka; Hiroyuki Inoue; Soichi Odawara; Yasuhiro Takada; Yasue Niwa; Masayuki Fujiwara; Norihiko Kamikonya; Shingo Yamamoto; Shozo Hirota
Journal:  Oncol Lett       Date:  2013-11-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.